This study will evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) plus ribavirin (RBV) in treatment-naive adults with chronic genotype 3 hepatitis C virus (HCV) infection.
This study is currently recruiting participants Locations in Canada
First received: April 7, 2015
Last updated: NA
Last verified: April 2015
For more info